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Abstract
Purpose Neurotensin (NT) and its high affinity receptor
(NTR1) are involved in several neoplastic processes. Thus,
NT-based radiopharmaceuticals are potential tracers for
targeted diagnosis and therapy of NTR-positive tumours.
A new analogue based on NT(8–13), NT-XIX, with the
three enzymatic cleavage sites stabilised, was synthesised
and tested.
Methods The synthesis was performed by Boc strategy.
Labelling with 99mTc/188Re was performed using the tricar-
bonyl technique. Metabolic stability was tested in vitro and
in vivo. NT-XIX was further characterised in vitro in HT-29
cells and in vivo in nude mice with HT-29 xenografts.
Results NT-XIX showed much longer half-lives than non-
stabilised analogues. Binding to NTR1 was highly specific,
although the affinity was lower than that of natural NT.
Bound activity rapidly internalised into HT-29 cells and 50%
remained trapped after 24 h. In the time-course biodistribu-
tion, the highest uptake was found in the tumour at all
p.i. times. In vivo uptake was specific, and accumulation of
activity in the kidneys was low. Radioactivity clearance from
healthy organs was faster than that from the tumour, resulting
in improved tumour-to-tissue ratios and good SPECT/CT
imaging. Treatment with 188Re-NT-XIX (30 MBq, in three
or four fractions) decreased tumour growth by 50% after
3 weeks.
Conclusion The high in vivo stability and the favourable in
vivo behaviour makes NT-XIX an excellent candidate for
the imaging and therapy of NTR1-positive tumours.
Keywords Neurotensin analogue . Tumour imaging .
SPECT/CT. Peptide receptor radionuclide therapy .
188Re . 99mTc . Radiolabelled peptides . Therapy (peptides) .
Endocrinology . Oncology
Introduction
Neuropeptide-based radiopharmaceuticals are interesting
compounds for tumour localisation and therapy, as has been
demonstrated with radiolabelled somatostatin (sst) analogues
for sst-receptor-positive tumours [1, 2]. Many tumours lack
sst receptors but over-express other neuropeptide receptors,
which have therefore become potential targets. This is the
case with neurotensin (NT) and NT receptors (NTR), which
have been associated with neoplastic progression of human
cancers such as lung, pancreatic, colon, prostate and breast
cancers [3–4].
NT is a tridecapeptide originally isolated from calf
hypothalamus [5]. It fulfils a dual function: neurotransmitter
or neuromodulator in the nervous system and local
hormone in the periphery [6, 7]. Three NTR subtypes have
been described [8]. NTR1 and NTR2 are G-protein-coupled
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receptors, whereas NTR3 is a single trans-membrane
domain type I receptor, showing homology with sortilin
[9]. Most NT actions at the central and peripheral levels are
mediated by NTR1. The role of NTR2 is still controversial,
and little is known regarding the physiological functions of
NTR3. Localisation of NTR3 is predominantly intracellular
in close proximity to the nucleus and seems to be involved
in the internalisation and trafficking of NT [10]. High over-
expression of NTR1 has been found in several human
tumours [3, 4]. For example, NTR1 incidences of 75–88%
and 91% have been reported for exocrine pancreatic
carcinoma [11, 12] and invasive ductal breast cancer [13],
respectively. The high expression of NT receptors found in
exocrine pancreatic cancers is of special interest. Whereas
significant progress has been made in the management of
many other forms of cancer, pancreatic cancer remains an
enigma and continues to be highly prevalent in western
countries, where it is the fifth leading cause of death from
cancer [14]. The vast majority of pancreatic cancers are
diagnosed at an advanced stage, when the tumours are no
longer resectable and metastasis has already occurred.
Souazé et al. [13] recently reported on the role of NT and
NT receptors in breast cancer progression. Expression of
NTR in breast cancers is an early event, which is involved
in neoplastic transformation. Breast cancer is the most
common form of cancer in females and, despite the decline
in breast cancer deaths in the last decades, is still the second
most fatal cancer in women after lung cancer [15]. The
development of new early diagnostic assays and novel
therapeutic modalities could have a major impact on the
treatment of these cancers. Over-expressed NTR could be
targeted with radiolabelled NT analogues and would offer
an interesting tool for tumour imaging and subsequent
therapeutic intervention. The main drawback of natural NT
is its rapid degradation in plasma. The three cleavage sites
in the metabolic deactivation of NT(8–13) are Arg8-Arg9,
Pro10-Tyr11 and Tyr11-Ile12 [16]. Modification of Arg8-Arg9
and Tyr11-Ile12 led to increased plasma stability, high
affinity for NTR1 and also good in vivo tumour uptake
[17–19]. With one analogue (NT-XI), visualisation of the
tumour of a patient with ductal pancreatic adenocarcinoma
was possible, which demonstrates the potential utility of NT
analogues for imaging of these tumours [20].
Tc and Re are transition metals of the same group of the
periodic table and, thus, share similar chemical properties.
In low oxidation states, the organometallic precursor fac-
[M(CO)3(H2O)3]
+ core (M=Tc, Re) forms stable complexes
that are small and kinetically inert. Therefore, Tc(I)/Re(I)
represent an attractive pair to label low molecular weight
molecules for diagnostic imaging and targeted radiotherapy.
99mTc shows ideal physical properties (half-life=6.02 h;
γ-emission energy=140 keV, 89%) for diagnostic imaging,
and 188Re has favourable decay properties (half-life=
17.0 h; β-emission energy=2.12 MeV; γ-emission energy=
155 keV, 15%) for potential therapeutic application.
Materials and methods
Synthesis of NT-XIX and radiolabelling
Peptide solid-phase synthesis was carried out on a Merrifield
resin, using a semi-automatic Labortec Peptide Synthesizer
SP640B. (NαHis)Ac (retro[Nα-carboxymethyl-histidine])
was coupled to the N-terminus as a ligand for labelling
with 99mTc and 188Re. The synthesis of NT-XIX (Table 1)
was performed as described in detail by Maes et al.
[21]. Radiolabelling with 99mTc (99Mo/99mTc generator,
Mallinckrodt, Petten, The Netherlands) was performed as
recently described [22, 23]. Briefly, 1 to 10 GBq/mL
pertechnetate was added to the mixture of sodium boranocar-
bonate, borax, potassium–sodium tartrate tetrahydrate and
sodium carbonate and heated for 20 min at 100°C. The
solution was cooled and neutralised (pH 6.5). This solution
Table 1 Stability and affinity of different radiolabelled NT analogues
Analogue Amino acid sequence Metabolic stability (t1/2)
In vitro In vivo Affinity
Human plasma HT-29 cells Blood Kd (nmol/L)
99mTc-NT-IIa (NαHis)Ac-Arg-Arg-Pro-Tyr-Ile-Leu 5.6 min n.d. <1 min 0.3±0.2
99mTc-NT-Xa (NαHis)Ac-Arg-Arg -Pro-Tyr-Tle-Leu 4 h 2 h n.d. 0.2±0.1
99mTc-NT-VIIIa (NαHis)Ac-(N-CH3)-Arg-Lys-Pro-Tyr-Tle-Leu 20 days 4.2 h n.d. 1.8±0.9
99mTc-NT-XIa (NαHis)Ac-Lys-<(CH2NH)-Arg-Pro-Tyr-Tle-Leu 21 days 4.5 h n.d. 0.5±0.3
99mTc-NT-XIIa (NαHis)Ac-Arg-(N-CH3)-Arg -Pro-Tyr-Tle-Leu 21 days 6.5 h 0.75 h 2.0±1.6
99mTc-NT-XIX (NαHis)Ac-Arg-(N-CH3)-Arg-Pro-Dmt-Tle-Leu 28 days 2.4 days 1.4 h 15.0±9.2
The modifications in the binding sequence are marked in bold.
(NαHis)Ac Retro[Nα -carboxymethyl-histidine], Tle tertiary-leucine, Dmt dimethyltyrosine, n.d. not determined
a Previously published, for comparison [17–19, 23]
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was mixed with the NT-XIX analogue (0.02 μmol) and heated
at 75°C for 1 h. The final product was analysed and purified
with high-performance liquid chromatography (HPLC) to
eliminate the excess of free peptide and other impurities.
Radiolabelling with 188Re (188W/188Re generator, Oak
Ridge National Laboratories, USA) was performed as
follows: 7.5 mg NH3BH3 (0.25 mmol) in a closed 10 mL
penicillin vial were filled with a CO flow (2 mL/min for
10 min). In a second vial, 20 μl 1 mmol/L peptide solution
was mixed with 60 μL 4 M HCl, 0.25 mL 0.5 M 2-(N-
morpholino)ethanesulfonic acid (MES), 5 mg sodium
ascorbate and 1 mL generator eluate (perrhenate, 50 MBq
to 0.5 GBq/mL). This solution was purged with argon
(10 mL/min for 2 min), then transferred to the vial with the
reducing agent and heated at 75–80°C for 4 h. The pH was
6.5 to 7. The final product was purified with HPLC.
Cell culture
The human colon adenocarcinoma HT-29 cells, from which
the human NT1 receptor was originally cloned [24], were
used. HT-29 cells were obtained from the European
Collection of Cell Culture (ECACC, Salisbury, England,
UK). Cells were maintained in McCoy’s 5A-GLUTAMAX
I supplemented with 10% FCS, 100 IU/mL penicillin,
100 μg/mL streptomycin and 0.25 μg/mL amphotericin B
(Invitrogen AG, Basel, Switzerland). Cells were cultured at
37°C in a humidified incubator under an atmosphere
containing 5% CO2 and subcultured weekly.
In vitro metabolic stability
In vitro stability was analysed in human plasma and HT-29
cells as previously described [17]. Plasma samples were
incubated at 37°C with 99mTc-NT-XIX 0.2 pmol/mL for
different times (up to 24 h). After incubation, proteins were
precipitated by mixing 0.25 mL of plasma sample with
0.75 mL of ethanol/acetonitrile (1:1), and the mixture
centrifuged at 14,000×g for 10 min. The supernatant was
filtered and analysed by HPLC using a Nucleosil® 100-5
C18 column (Macherey-Nagel, Oensingen, Switzerland) and
equipped with a radioactivity detector (Radiomatic Model
525TR). The percentage of intact peptide was determined
from the radioactivity chromatograms, in which the peaks
of intact peptide and the different degradation products
were represented. For studies of degradation in cells, intact
HT-29 cells (2×106 cells/mL) were incubated at 37°C with
99mTc-NT-XIX 0.2 pmol/mL for different times (up to
24 h). After incubation, cells were lysed with an ultrasound
probe (Skan) at 4°C (duty cycle: 40; output control: 4;
4 min), proteins were precipitated with ethanol/acetonitrile
(1:1) and the suspension was filtered. A sample of the
filtrate was analysed by HPLC as above.
In vivo metabolic stability
In vivo stability was analysed in Balb/c mice. Animals were
injected i.v. with 99mTc-NT-XIX (25 MBq). At 1- and
2-h post-injection (p.i.), mice were sacrificed, and blood,
urine, kidney and liver were collected and kept in ice. Liver
and kidney were suspended in phosphate-buffered saline
(PBS) with 1% Triton X-100 and homogenised. All the
samples were then centrifuged at 14,000×g for 5 min. The
supernatant of each sample was collected in tubes, and
the pellets were resuspended in PBS and centrifuged again.
The final supernatants were collected in the corresponding
tubes. Proteins were precipitated with ethanol/acetonitrile
(1:1) and centrifuged at 14,000×g for 10 min, the pellet
was discarded and the supernatant was filtered. A sample of
the filtrate was analysed by HPLC as above.
Binding assays
Binding assays were performed with HT-29 cells at
confluence as already described [20, 22]. For saturation
studies, cells were incubated in triplicate with increasing
concentrations (0.3–30 nmol/L) of purified 99mTc-NT-XIX
for 1 h at 37°C. After washing with PBS to eliminate
unbound activity, cells were lysed with 1 N NaOH at 37°C.
Bound radioactivity was measured in a γ-counter (Packard
Canberra Cobra II Auto-Gamma counter, Meriden, USA).
Non-specific binding was determined with 1 μmol/L
unlabelled NT(8–13).
Internalisation/efflux
Internalisation studies were performed as previously de-
scribed [17, 19], with HT-29 cells at confluence. Inter-
nalisation of 99mTc-NT-XIX (10 kBq) was evaluated at
37°C up to 2 h. Surface bound activity was removed by
acid wash (50 mmol/L glycine-HCl/100 mmol/L NaCl,
pH 2.8) at room temperature, and internalised peptide was
recovered with 1 N NaOH. Non-specific internalisation was
determined in the presence of 1 μmol/L NT(8–13). Results
are expressed as a percentage of the maximal activity
associated with the cells (surface bound + internalised) and
as a percentage of internalised activity in relation to the
total activity added.
For efflux experiments, confluent cells in 6-cm Petri
dishes were incubated at 37°C, with 99mTc-NT-XIX
(10 kBq) for 1 h to allow maximal internalisation. Then,
the medium was discarded, and the cells were washed with
cold PBS. New medium was added, and the cells were
incubated at 37°C. At different times (30 min to 24 h), the
medium was collected. Membrane-bound activity was
recovered by acid wash and internalised activity with 1 N
NaOH. Released analogue (activity in the medium),
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membrane-bound analogue and internalised analogue were
measured by γ-counting. Results are expressed as the
percentage of total activity at each time point.
Biodistribution studies
All animal experiments were conducted in compliance with
the Swiss animal protection laws and the guidelines for
scientific animal trials established by the Swiss Academy of
Medical Sciences and the Swiss Academy of Natural
Sciences. Female CD-1 Nu/Nu mice (6- to 8-week-old,
Charles River, Sulzfeld, Germany) were inoculated with 5×
106 HT-29 tumour cells in the left flank and in the shoulder.
When tumours were palpable (10–12 days), mice received
99mTc-NT-XIX or 188Re-NT-XIX (3.5–4 MBq/mouse, pep-
tide mass of approximately 0.5 ng) administered intrave-
nously (i.v.). Animals were sacrificed by cervical dislocation
at different p.i. times (1.5, 5 and 24 h; additionally at 48 h for
188Re-NT-XIX) and then dissected. Different organs and
tissues were collected and weighed, and the radioactivity was
determined by γ-counting. A minimum of three animals were
used per time point. Results are expressed as a percentage of
injected dose per gram of tissue (%ID/g). In blockade
experiments, mice received 3.5–4 MBq of 99mTc-NT-XIX
co-injected i.v. with 0.3 mg/mouse of NT-XI administered
intravenously, a doubly stabilised analogue of the same
series with good affinity for NTR1 [18]. Animals were
sacrificed at 1.5 h p.i., the different organs/tissues were
removed and the radioactivity was measured in a γ-counter.
SPECT/CT imaging
Post-mortem studies were performed 1.5 h after i.v. injection
of 99mTc-NT-XIX (3.5–4 MBq). Images were obtained on
an X-SPECT™-system (Gamma Medica, Northridge, USA)
equipped with a single-head SPECT device and a CT
device. SPECT data were acquired and reconstructed with
the software LumaGEM. CT data were acquired by an
X-ray CT-system (Gamma Medica™) and reconstructed
with the software Cobra. Fusion of SPECT and CT data
was performed with the software IDL Virtual Machine™.
Images were generated with the software Amira™.
Preliminary therapy studies
Therapy studies were conducted in mice with HT-29
xenografts. Animals were divided into four groups. The
control group received i.v. the vehicle (saline) with no activity.
Treated groups received i.v. 188Re-NT-XIX 30 MBq/mouse
in fractionated doses: 2 of 15 MBq (at days 0 and 3), 3 of
10 MBq (at days 0, 3 and 6) and 4 of 7.5 MBq (at days 0, 3,
6 and 9). The growth of the tumours was monitored for
3 weeks starting the day of the first injection (day 0). A
calliper was used to measure the longest (L) and the shortest
(W) dimensions of the tumours. The tumour was assumed as
an ellipsoid, and its volume was calculated with the formula:
Vt=(π/6)LW
2. The relative volume of tumours, Vr, was
defined as Vr=Vt/V0, where Vt was the measurement at time t
(days after the first injection), and V0 was the measurement
at day 0 (day of the first injection).
Statistical analysis
Differences between blocked and control groups in the
biodistribution studies were analysed by Welch-corrected
t test (variances between the groups are significantly
different). p<0.01 was considered statistically significant.
One-way ANOVA, followed by Tukey’s comparison
test, was used to analyse differences in the kidney, liver and
tumour uptakes between the new stable NT analogue and
previous doubly stabilised analogues. p<0.01 was considered
statistically significant.
Differences in relative tumour volume were analysed by
one-way ANOVA (Tukey’s as post hoc test). p<0.05 was
considered statistically significant.
Results
Radiolabelling
After labelling with 99mTc, the yield was higher than 95%. In
the HPLC chromatogram, the peak of 99mTc-NT-XIX
appeared at a retention time of 17.1 min (Fig. 1a). Labelling
with 188Re resulted in lower yields, 75–80%. The main peak
in the HPLC chromatogram, with a retention time of
16.9 min, corresponded to 188Re-NT-XIX. The second peak,
at a retention time of 3.5 min, represented perrhenate
(Fig. 1b). Both 99mTc-NT-XIX and 188Re-NT-XIX were
purified by HPLC to eliminate the excess of cold peptide and
other impurities. Perrhenate was not detectable in the HPLC
of the purified 188Re-NT-XIX.
The chemical stability of 188Re-NT-XIX was tested in
phosphate buffer up to 10 GBq. The complex was stable for
at least 48 h, and, after 72 h, 70% of the complex was still
stable.
In vitro metabolic stability
The three changes introduced in NT-XIX conferred a high in
vitro stability to the molecule. Most 99mTc-NT-XIX was still
intact after 24 h at 37°C. Plasma half-life estimated in
28 days was significantly improved compared to that of the
non-stabilised analogue 99mTc-NT-II (only 5.6 min) and
similar to that of previous analogues [17–19, 23]. Stability in
HT-29 cells was also very high, and 70% of 99mTc-NT-XIX
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was still intact after 24 h at 37°C. The half-life in HT-29 cells
was 2.4 days and was an important improvement compared
to doubly stabilised analogues such as 99mTc-NT-XI and
99mTc-NT-XII, for which the half-lives in tumour cells were
not higher than 6.5 h [17–19]. Data are presented in Table 1.
In vivo metabolic stability
99mTc-NT-XIX was more rapidly metabolised in vivo than in
vitro, with a half-life in blood of 1.4 h (Table 1). However, it
was more stable than the doubly stabilised analogue 99mTc-
NT-XII (half-life of 45 min in vivo, Table 1) and much more
stable than the unmodified analogue 99mTc-NT-II. Most
99mTc-NT-II was metabolised after 1 min (less than 9%
was intact in blood at this time), whereas about 40% of
99mTc-NT-XII and more than 80% of 99mTc-NT-XIX
remained intact after 1 h.
Binding assays
Binding of 99mTc-NT-XIX to intact cells was saturable and
highly specific. The affinity of 99mTc-NT-XIX remained at
nanomolar level (Kd of 15.0 nmol/L), although it was lower
than that obtained for 125I-NT (1.6 nmol/L), the non-
stabilised 99mTc-NT-II (0.3 nmol/L) and the stabilised
99mTc-NT-VIII (1.8 nmol/L), 99mTc-NT-XI (0.5 nmol/L) or
99mTc-NT-XII (2.0 nmol/L). Results are summarised in
Table 1.
Internalisation/efflux
After binding, rapid internalisation of the complex NT
analogue-NTR1 has been reported [25]. Internalisation of
99mTc-NT-XIX into HT-29 cells was also rapid and time
dependent. It sharply increased during the first 30 min with
maximal internalisation rates of 90%. It then reached a
plateau and remained stable for at least 2 h, with a pattern
similar to other 99mTc-NT analogues (Fig. 2a). Inter-
nalisation related to the total activity added increased with
time up to 5.5% after 2 h. Other 99mTc-NT analogues
exhibited higher internalisation rates, which may be
ascribed to their higher affinity for the receptors. However,
the less stable analogues also showed an important decrease
a
81447
61085
40723
20361
b
0
0 5 10 15 20 25
Time (min)
Time (min)
Co
un
ts
 (c
pm
)
Co
un
ts
 (c
pm
)
18957
75629
56871
37914
0
0 5 10 15 20 25
188 ReO4
-
Fig. 1 Representative HPLC radiochromatograms after labelling.
a 99mTc-NT-XIX. b 188Re-NT-XIX
Fig. 2 Internalisation in HT-29 cells after incubation at 37°C.
a Internalisation/efflux related to the activity associated with the cells.
b Internalisation related to total activity
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after 1 h, likely due to a rapid degradation in the tumour
cells. Results are depicted in Fig. 2b.
Concerning the release of the activity after maximal
internalisation, approximately 50% of the internalised
activity remained inside the cells after 24 h at 37°C
(Fig. 2a). Radioactivity retention in tumour cells was
comparable to other doubly stabilised 99mTc-NT analogues
of the same series [19] and much higher than that of the less
stable analogue 99mTc-NT-X or the non-stabilised 99mTc-
NT-II (Fig. 2a).
Biodistribution studies
At 1.5 h p.i., uptake of 99mTc-NT-XIX in most healthy
organs was low. The highest uptake was found in the
intestinal tract and in the tumour, 6.0±2.3% and 5.9±1.1%
ID/g, respectively (Fig. 3a). Renal uptake, 3.6±1.0% ID/g,
was significantly lower than that found for previously
reported analogues such as NT-VIII, NT-XI and NT-XII
(10.3%, 14.6% and 9.1% ID/g, respectively; Fig. 4) [17–
19]. After 5 h, a large amount of activity had cleared from
most of the organs. Interestingly, tumour activity wash-out
was lower than that of intestine, NTR-positive tissue.
Thus, tumour uptake was the highest at 5 h p.i. (5.2±
0.5% ID/g), exceeding the 3.4±0.7% ID/g in intestine
(Fig. 3a). At 24 h p.i., a similar biodistribution pattern was
observed, with the highest uptake in the tumour (2.5±
0.2% ID/g). Moreover, from 5 to 24 h, a faster clearance of
activity was found in the intestine compared to the tumour.
Tumour-to-blood ratios at 1.5 and 5 h were similar to our
previous NT analogues [17, 19]; however, at 24 h, higher
tumour-to-blood ratios were found for 99mTc-NT-XIX.
Fig. 3 Biodistribution in mice
with HT-29 tumour xenografts.
a Time-course biodistribution:
99mTc-NT-XIX vs. 188Re-NT-
XIX (3.5–4 MBq/mouse i.v.
each). b Biodistribution at 1.5 h
p.i.: unblocked vs. blocked.
Blocked animals received
99mTc-NT-XIX co-injected with
unlabelled NT-XI [18],
0.3 mg/mouse. Data represent
percentage of injected dose (ID)
per gram of tissue (mean±SD,
3–5 animals). *p<0.01 and
**p<0.001 vs unblocked group,
Welch-corrected t test
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Tumour-to-kidney and tumour-to-liver ratios (Table 2) were
also significantly better for the new analogue at all p.i.
times [17–19].
In blockade studies, a similar accumulation was found in
most organs with the exception of the tumour, intestine and
stomach (NTR1-positive tissues), in which the inhibition
was statistically significant, 78%, 84% and 61%, respec-
tively (Fig. 3b). The blockade was only effective in the
NTR-positive tissues, which demonstrates that the in vivo
uptake for 99mTc-NT-XIX was very specific and due to
interaction with NTR. NT-XI (0.3 mg/mouse) was used to
displace 99mTc-NT-XIX since NT(8–13) was not so
effective (data not shown). In the in vitro tests, non-specific
binding was always tested with NT(8–13) and found to be
negligible. In vitro, we used inhibitors of peptidases that
prevent metabolism. However, in vivo NT(8–13) is suscep-
tible to rapid enzymatic degradation, which would explain
why the inhibition was not statistically significant. NT-XI
showed longer plasma half-life than NT(8–13), and it was
likely to be more stable in vivo. Therefore, there would be a
sufficient amount of peptide able to displace the in vivo
binding of 99mTc-NT-XIX to the NTR-positive tissues.
The biodistribution of 188Re-NT-XIX was comparable to
that of 99mTc-NT-XIX at all p.i. times (Fig. 3a). Uptake in
blood was slightly higher, whereas uptake in receptor-
positive tissues was slightly lower. This resulted in slightly
lower tumour-to-tissue ratios for 188Re-NT-XIX compared
to 99mTc-NT-XIX, especially tumour-to-blood ratios.
SPECT/CT imaging
The tumour xenografts could be perfectly visualised by
SPECT/CT imaging with 99mTc-NT-XIX at 1.5 h p.i.
(Fig. 5a). The specificity of the tumour uptake was also
demonstrated since no activity was found in the tumour of
the animal receiving co-injection of 99mTc-NT-XIX and
unlabelled NT-XI (Fig. 5b). The favourable biodistribution
of NT-XIX resulted in much better tumour imaging than
with previous analogues [17, 19].
Therapy studies
Tumour volume progressively increased in the control
group. The group administered with two i.v. injections of
188Re-NT-XIX 15 MBq/mouse (days 0 and 3) showed a
Fig. 4 Comparison of the uptake of stabilised 99mTc-NT analogues in
kidney, liver and HT-29 tumour xenografts at 1.5 h p.i. The analogues
99mTc-NT-VIII, 99mTc-NT-XI and 99mTc-NT-XII have been previously
reported [17–19]. Statistical analysis (one-way ANOVA+Tukey’s post
hoc test): (a) p<0.001 vs. 99mTc-NT-VIII, 99mTc-NT-XI and 99mTc-
NT-XII; (b) p<0.001 vs. 99mTc-NT-XII; (c) p<0.01 vs. 99mTc-NT-XI
Table 2 Tumour-to-tissue ratios in nude mice with HT-29 tumour xenografts
Time (h) Analoguea Tu/Bl ratio Tu/Ki ratio Tu/Li ratio
1.5 99mTc-NT-XI 11.7±3.9 0.4±0.1 2.0±0.6
99mTc-NT-XII 12.2±1.0 0.9±0.8 0.9±0.1
99mTc-NT-XIX 13.1±4.9 1.7±0.4** 2.3±0.7§§
5 99mTc-NT-XI 20.6±10.8 0.2±0.1 1.3±0.7
99mTc-NT-XII 21.4±3.7 0.9±0.3 2.0±0.6
99mTc-NT-XIX 28.1±2.5 1.9±0.1**,§§ 4.5±0.7**,§§
24 99mTc-NT-XI 69.5±17.9 0.2±0.0 2.0±0.3
99mTc-NT-XII 79.6±19.0 1.2±0.1 4.6±0.7
99mTc-NT-XIX 118.1±13.6* 2.6±0.1**,§§ 8.3±0.6**,§§
Data are mean±SD of individual ratios (n=3–7).
a Analogues NT-XI and NT-XII previously published, for comparison [18–19]
Tu tumour, Bl blood, Ki kidney, Li liver
*p<0.01, **p<0.001 vs 99m Tc-NT-XI, § p<0.01, §§ p<0.001 vs 99m Tc-NT-XII (one-way ANOVA+Tukey’s post hoc test)
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slower tumour growth in the first week compared to the
control. Afterwards, tumour growth was comparable to the
control group (Fig. 6a). Inhibition of tumour growth after
injection of 188Re-NT-XIX, either in three fractions of
10 MBq (days 0, 3 and 6) or in four fractions of 7.5 MBq
(days 0, 3, 6 and 9), was similar. The therapeutic effect of
3×10 and 4×7.5 MBq was statistically significant in the
first 6 days. However, the consistent inhibition in tumour
growth observed afterwards in both groups was not
significantly different from controls. Tumour growth
decrease at the end of the experiment was 55% and 47%
for 3×10 and 4×7.5 MBq, respectively (Fig. 6a). Tumour
doubling time also increased from 4.8±0.5 days in the
control group to 6.3±1.8 and 6.0±1.0 days in the groups
treated with 3×10 and 4×7.5 MBq of 188Re-NT-XIX
(Fig. 6b).
Discussion
Bioactive peptides regulate a large variety of physiological
functions and also play a crucial role in pathological
b
T1
T2
L
B T1T2
L
I
I
a
T2
T2 T1
BL
I
T1
Transaxial sections
Sagittal sectionCoronal section
Coronal section
Transaxial sections
Sagittal section
Fig. 5 SPECT/CT images of mice bearing HT-29 tumour xenografts
1.5 h after i.v. injection of 99mTc-NT-XIX (3.5–4 MBq). a Unblocked.
b Blocked. Blocked animals received 99mTc-NT-XIX co-injected with
unlabelled NT-XI [18], 0.3 mg/mouse. T1 Upper tumour, T2 lower
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conditions such as tumour growth and tumour progression,
inflammation, platelet aggregation or apoptosis. These
peptides exert their actions through membrane-bound recep-
tors at very low concentrations. Peptide receptors are over-
expressed on various cancer cells and represent attractive
targets for tumour imaging and therapy. Over-expression of
NT receptors has been reported in breast, pancreatic, prostate,
lung and colon cancers [3–6]. Peptide-based conjugates
consisting of NT analogues linked to radionuclides could be
interesting radiopharmaceuticals to selectively deliver radio-
nuclides to receptor-expressing tumour cells. NT-XIX is a
new NT(8–13) derivative with modifications at the three
cleavage sites (Table 1), which led to a substantial increase
in metabolic stability. The higher stability in vivo compared
to previous stabilised NT analogues is of special interest
since a higher amount of intact peptide would reach the
tumour area, increasing the probability of binding to the
receptors. Moreover, 99mTc-NT-XIX retained affinity for
NTR1 in the nanomolar range (Table 1), it was rapidly
internalised into HT-29 cells after binding and more than
half of the internalised radioactivity was still trapped inside
the cells after 24 h (Fig. 2a), which is important since
retention of radioactivity in the tumour is essential for the
therapeutic efficacy of a radiopharmaceutical.
The interest of this new NT analogue was confirmed in
vivo in nude mice with HT-29 xenografts. The highest
uptake was found in the tumour, whereas kidney uptake and
liver uptake were 1.6 and 2.0 times lower, respectively
(Fig. 3a). High kidney accumulation is a widely reported
problem with radiolabelled neuropeptide analogues [23,
26–29], and, therefore, the low kidney uptake observed for
99mTc-NT-XIX even at an early time point is an interesting
feature (Fig 4). In vivo uptake of 99mTc-NT-XIX was due to
specific interaction with NTR, as demonstrated in blockade
experiments (Fig. 3b), in which the uptake in the tumour
and in the gastrointestinal tract, receptor-positive tissue [3]
was significantly inhibited. In contrast to the rapid
radioactivity clearance from most organs in the first 24 h
p.i., the activity was retained longer in the tumour (Fig. 3a),
which matches the results of the in vitro externalisation
studies. Interestingly, 99mTc-NT-XIX showed the best
tumour-to-kidney ratios obtained with an NT analogue,
radiolabelled with either 99mTc [20–22, 26, 34] or with 111In
[30, 31]. The tumours were clearly delineated by SPECT/
Fig. 6 Therapeutic effect of 188Re-NT-XIX (total accumulated dose
30 MBq/mouse) in mice with HT-29 tumour xenografts. a Time-
course tumour growth. Data are expressed as the volume of tumours
relative to that in the same animals immediately before the first
injection (mean±SD of 4–7 animals). Statistical analysis (one-way
ANOVA+Tukey’s post hoc test): p<0.05 all treated groups vs. control
at days 1 and 2 after first injection; p<0.05 groups 3×10 and 4×
7.5 MBq vs. control at day 6 after first injection. b Comparison of
tumour volume and tumour doubling time
b
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CT (Fig. 5a). A higher accumulation was found in tumour
than in any other tissue, which corroborates the results
obtained in the biodistribution studies. The specificity of
the tumour uptake was also demonstrated by SPECT/CT
(Fig. 5b). SPECT/CT imaging with 99mTc-NT-XIX was
superior to that with the best doubly stabilised analogue
99mTc-NT-XII [19] and would confirm its clear potential for
future application as a diagnostic radiopharmaceutical.
NT-XIX showed a comparable biodistribution radio-
labelled with 99mTc and 188Re (Fig. 3a). In preliminary
therapeutic studies, 188Re-NT-XIX (total dose of 30 MBq/
mouse) was able to significantly inhibit the growth of HT-29
tumour xenografts in nude mice. 188Re-NT-XIX, injected
either in three or in four fractionated doses, reduced tumour
growth by 50% (Fig. 6), suggesting that 188Re-NT-XIX
holds the potential to be used as a radiotherapeutic agent.
The results reported here demonstrate that stability plays
a very important role in the tumour uptake of radiolabelled
NT analogues. Despite a slight decrease in receptor affinity
and a lower rate of internalisation, in vivo tumour uptake
(Fig. 4) was similar to that of 99mTc-NT-XII [19] and higher
to that of 99mTc-NT-VIII or 99mTc-NT-XI [18], and this is
likely due to the longer in vivo stability. Other interesting
findings were the low kidney and liver uptakes obtained for
this derivative (Figs. 3a and 4). The persistent accumulation
of radiolabelled peptides in normal tissues could compro-
mise their potential use as therapeutic agents due to
possible radiation toxicity. It is well known that the kidneys
are a major site in the catabolism of low molecular weight
molecules. However, radiometal-chelated amino acids are
not rapidly excreted since they bind to intracellular metal-
binding proteins and remain trapped. High kidney uptake
may result in renal toxicity [31] and, therefore, have a
negative impact on the potential therapeutic efficacy of a
peptide radiopharmaceutical. Different methods have been
tried to reduce kidney uptake such as administration of
basic, cationic amino acids (L-lysine and arginine) or
infusion of low doses of a gelatin-based plasma expander
[32–34]. In the case of radiolabelled NT analogues that can
bind to intestinal NT receptors, the intestine may also be an
important dose-limiting organ. In contrast to the kidneys,
the intestine is an organ with a rapid cell turnover and
symptoms of intestinal radiation toxicity appear early,
during or shortly after radiation therapy. Acute radiation
enteropathy results in mucosal inflammation and is often
self-limiting and reversible. Less frequent, chronic bowel
toxicity may occur later and is characterised by progressive
intestinal wall fibrosis and vascular sclerosis. Different
approaches have been evaluated to protect the intestine
against radiation toxicity such as interleukin-11, immuno-
modulators, inhibitors of proteinase-activated receptors,
inhibitors of thrombin and statins [35–39]. Prophylaxis with
antioxidant and radioprotectant agents such as amifostine
may also be considered to limit possible radiation damage
in normal tissues [40]. In the therapy studies with 188Re-
NT-XIX, an inhibition of tumour growth was obtained after
injection of three or four fractions. The possibility of using
fractionated doses would reduce injury in most normal
tissues. Moreover, radioactivity was cleared more rapidly
from healthy organs than from tumour, and, therefore, the
risk of radiation toxicity in normal tissues with this
analogue would also be lower.
Conclusion
In the present study, a new stabilised NT analogue is
introduced. Its high stability was accompanied by a high
tumour uptake and lower kidney uptake, which led to tumour-
to-kidney ratios much better than those found for other
derivatives already reported. The clear visualisation of
tumours by SPECT/CT with NT-XIX labelled with the γ-
emitting radionuclide 99mTc, together with the promising
results in preliminary therapeutic studies (labelled with the
β-radionuclide 188Re), justifies the interest in such a peptide.
Therefore, we conclude that the new analogue is an excellent
candidate for future application in imaging and therapy of
NTR-positive tumours. Clinical studies will help to deter-
mine the potential utility of NT-XIX in human oncology.
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